slides were screened under fluorescent microscope (Leica 6000 M, Germany) using appropriate filters.
Discussion
Using both 2007 and 2013 ASCO/CAP scoring method on FISH technique, we found 10% of difference between two methods of scoring. Using FISH, we also investigated the frequency of polysomy 17 and its association with HER2 alteration in patients with invasive breast cancer. As polysomy 17 are relatively common in breast carcinoma, it is possible that HER2 FISH results can be misinterpreted. Vanden Bempt et al. reported that >40% of breast carcinomas with polysomy 17 [5] and Pu et al. reported 57.1% breast carcinoma with polysomy 17. [6] However, in the Indian population, our study Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre
Introduction
Breast cancer is the second most common cancer for women in the India. [1] Researches have shown that about 20-30% of the breast cancer patients have HER2 amplification or overexpression that is associated with a more aggressive phenotype and decreased survival. [2] Fluorescent in situ hybridization (FISH) is the gold standard because it was the strategy used during clinical trials and has proven clinical utility. Polysomy 17 indicates the presence of more than two copies of chromosome 17 and is reported in 13-46% breast carcinoma. [3] Amplification is by far the most common mechanism generating excess HER2 gene copies, polysomy occurs frequently. This has raised the question of whether increased HER2 protein expression can result not only from gene amplification but also from increased number of chromosome 17. The consequence would then be that patients with polysomy 17 tumors might be candidates for trastuzumab. [4] This study includes 557 breast cancer patients with equivocal HER2 test results by immunohistochemical staining (immunohistochemistry [IHC] 2+) with an aim to measure the impact of changed criteria of ASCO/CAP recommendation 2007 and 2013 as well as frequency of polysomy 17 and deletion of HER2 gene.
Materials and Methods

Sample collection and fixation protocol
Five hundred and fifty-seven cases with equivocal results on IHC (2+) from July 2010 to September 2013 were studied. Expression of HER2/neu IHC and FISH was analyzed.
Fluorescent in situ hybridization
FISH analysis was performed using the PathVysion HER2 probe kit (Vysis, USA). All procedures were followed according to the HER2 probe kit instruction manual (Vysis, USA). The
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. showed 19% breast carcinoma with polysomy 17. When we applied 2013 CAP scoring criteria, we found 14.6% increase in number for HER2 amplification with polysomy 17. As we shown one case in Figure 1 , polysomy17 with negative according to CAP 2007 guideline but when we applied 2013 CAP guideline on the same case, the case should be given positive with polysomy. When we re-evaluated the 82 cases that were HER2 nonamplified and polysomy 17 accompanied, we found that 12 (14.6%) cases could be defined as HER2 amplified. These 14.6% patients showed HER2 amplification may be suitable for anti-HER2 targeted therapy. There was a significant increase in the number of HER2 amplified cases, i.e., cases increase from 192 to 246 out of 557 cases. As recent study suggested that the presence of CEP17 alterations could identify a more aggressive subset of breast cancers that are nonresponsive to conventional therapy independently of HER2 amplification status. [7] Some researchers believe that polysomy 17 without HER2 amplification do not predict response to lapatinib in metastatic breast cancer. [7] Conclusion FISH results were evaluated (IHC2+ interpreted according to CAP 2007 guideline) with both 2007 and 2013 ASCO/ CAP scoring criteria, we identified significantly more HER2 positive cases as compared to cases evaluated using the 2007 criteria (P < 0.05). Polysomy of CEP17 is a crucial cause of misinterpretation of HER2 FISH result. Using the 2013 ASCO/ CAP scoring criteria on IHC2+ cases evaluate significantly higher in a number of HER2 amplification with polysomy of chromosome 17, which shows more patients appropriate for targeted treatment. Microsatellite studies on chromosome nine identified acquired uniparental disomy (UPD) as a common defect in MPN. V617F mutation in the Janus kinase 2 gene (JAK2) present in 95% of PV and >50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients. [1] New target gene CBL is associated with aberrations of chromosome 11q. [2] CBL exons 8 and 9 (11q23.3) mutations seen commonly in PMF and post MPN and rarer in PV and ET.
[1] Here we report a case of PV with 11q23 deletion with a stable disease.
(Continue on page 50...)
A 70-year-old male presented with pruritus for 1 year. Hemoglobin was 211 g/L, hematocrit-68.5%, total leucocyte count-20.6 × 10 6 /L, platelet count-470 × 10 9 /L with neutrophilic leukocytosis. Bone marrow was hypercellular with trilineage hyperplasia. Serum erythropoietin was 1.2 mIU/ml and JAK2 V617F from peripheral blood was positive. Cytogenetic analysis showed 46, XY with 11q23 deletion in 100% cells [ Figure 1 ]. He was started on biweekly phlebotomy, aspirin 75 mg once daily and hydroxyurea 500 mg once daily; maintaining a hematocrit of 45% and off phlebotomy for the last 8 months.
Cytogenetic abnormalities in PV being del (20q), del (13q), +8, +9 and chromosome 1 abnormalities and acquired UPD of 1p, 4q 7q, 9p, and 11q associated with homozygosity for mutations in MPL, TET2, EZH2, JAK2 and CBL respectively. [2] CBL mutations in myeloid malignancies are associated with 11q acquired UPD. [3] The present case compared with cases from other studies with chromosome 11 abnormalities in Table 1 . It's apparent from the literature that PV with chromosome 11 abnormalities has a chance of progression to AML. Hence, our index case has to be kept on close follow-up. Next generation sequencing based identification of
